GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 67.29 USD | -0.90% |
|
-0.53% | -16.94% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 27.6B 37.71B | Sales 2025 * | 27.98B 38.23B | Capitalization | 83.83B 115B |
|---|---|---|---|---|---|
| Net income 2024 * | 403M 551M | Net income 2025 * | 6.35B 8.68B | EV / Sales 2024 * | 3.7 x |
| Net Debt 2024 * | 18.15B 24.8B | Net Debt 2025 * | 12.68B 17.33B | EV / Sales 2025 * | 3.45 x |
| P/E ratio 2024 * |
193
x | P/E ratio 2025 * |
13
x | Employees | 18,000 |
| Yield 2024 * |
4.6% | Yield 2025 * |
4.82% | Free-Float | 99.89% |
More Fundamentals
* Assessed data
More news
Latest transcript on Gilead Sciences, Inc.
More recommendations
More press releases
| 1 day | -0.90% | ||
| 1 week | -0.53% | ||
| Current month | +3.21% | ||
| 1 month | +0.79% | ||
| 3 months | -8.07% | ||
| 6 months | -9.91% | ||
| Current year | -16.94% |
1 week
66.84
68.04
1 month
64.3368.37
Current year
64.3387.87
1 year
64.3387.87
3 years
57.1789.74
5 years
56.5689.74
10 years
56.56123.37
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 59 | 19-02-28 |
Andrew Dickinson
DFI | Director of Finance/CFO | 54 | 15-12-31 |
Flavius Martin
CTO | Chief Tech/Sci/R&D Officer | - | 21-04-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anthony Welters
BRD | Director/Board Member | 69 | 20-10-16 |
| Director/Board Member | 71 | 17-12-31 | |
Ted Love
BRD | Director/Board Member | 65 | 01-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.99% | 254 M€ | +11.80% | - | |
| 8.10% | 0 M€ | 0.00% | - | |
| 8.06% | 0 M€ | 0.00% | - | |
| 5.23% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-21 | 67.29 | -0.90% | 5,701,228 |
| 24-05-20 | 67.9 | +0.27% | 4,719,854 |
| 24-05-17 | 67.72 | -0.21% | 3,579,110 |
| 24-05-16 | 67.86 | +1.27% | 4,831,970 |
| 24-05-15 | 67.01 | -0.95% | 7,532,064 |
Delayed Quote Nasdaq, May 21, 2024 at 04:00 pm
More quotes
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
67.29
USD
Average target price
82.93
USD
Spread / Average Target
+23.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.94% | 83.83B | |
| +37.78% | 723B | |
| +30.88% | 598B | |
| -3.51% | 364B | |
| +19.94% | 331B | |
| +5.14% | 288B | |
| +16.62% | 244B | |
| -4.62% | 208B | |
| +10.13% | 210B | |
| +9.32% | 169B |
- Stock Market
- Equities
- GILD Stock